Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ligand Pharm
(NQ:
LGND
)
103.82
+0.20 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharm
< Previous
1
2
3
4
5
6
Next >
Ligand to Report Third Quarter Financial Results on November 7
October 26, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
October 26, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
OmniAb Business Combination Approved by APAC Shareholders
October 24, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
February 23, 2022
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
Earnings Scheduled For February 17, 2022
February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
Via
Benzinga
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
October 03, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
August 25, 2022
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
August 24, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals...
Via
Benzinga
Ligand Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 01, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Second Quarter Financial Results on August 8
July 22, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know
July 05, 2022
Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%...
Via
Benzinga
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
June 29, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
10 Biggest Price Target Changes For Monday
May 16, 2022
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.
Via
Benzinga
Ligand Reports First Quarter 2022 Financial Results
May 04, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter Financial Results on May 4
April 19, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
March 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger
March 24, 2022
Ligand Pharmaceuticals Inc (NASDAQ: LGND)
Via
Benzinga
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
March 23, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Tough Slogging Ahead for Investors, Diversification is Important
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Recap: Ligand Pharmaceuticals Q4 Earnings
February 17, 2022
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
February 17, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
February 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
Ligand to Report Fourth Quarter Financial Results on February 17
February 09, 2022
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
December 22, 2021
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.